For patients who meet EMBARK criteria but also show oligometastatic disease on PSMA PET, clinicians are adopting a pragmatic approach. They combine the evidence-backed systemic hormone therapy from the trial with targeted radiation of metastatic sites, aiming to prolong the time until therapy needs to be restarted.

The Capitello 281 study established PTEN deficiency not just as a biomarker, but as a distinct subpopulation of prostate cancer. This subtype has a poor prognosis, higher rates of symptomatic bone complications, and often progresses with a relatively low Prostate-Specific Antigen (PSA), making it biologically distinct from other prostate cancers.

The prevalence of PTEN loss is not static; it increases significantly as prostate cancer advances. While less common in localized disease, it can be found in up to 25% of patients with metastatic disease. This escalating frequency with disease progression underscores its role as a key driver of cancer advancement and a critical therapeutic target in later stages.

The AKT pathway, activated by PTEN loss, drives cancer growth independently of the androgen receptor, which controls PSA production. This discordance means clinicians cannot rely on PSA alone and must use systematic imaging to detect progression in this specific patient subgroup.

Prostate cancer patients harboring PTEN loss often experience immediate pain reduction within one to two months of starting ADT plus ARPI doublet therapy. However, Dr. Neeraj Agarwal cautions that this symptom relief can be misleading: tumors with targetable alterations like PTEN deficiency or HRR mutations progress significantly faster. Oncologists must counsel patients not to forgo adding third-agent targeted therapy simply because their symptoms improved rapidly.

In the CAPITELO-281 trial, one-third of prostate cancer patients with PTEN deficiency demonstrated radiographic or clinical progression without meeting standard PSA progression criteria. Dr. Neeraj Agarwal stresses that clinicians should not rely on PSA monitoring alone in this cohort. Instead, oncologists must convince reluctant patients to undergo routine CT, bone, or PSMA PET scans to avoid catastrophic consequences like paraplegia from unmonitored spinal cord compression.

In patients with PTEN loss, cancer growth is driven by the PI3K-AKT pathway, which doesn't activate the PSA gene. This can lead to significant disease progression with a low or stable PSA, making PSA a poor surrogate for disease activity in this sub-population.

High-risk features in localized prostate cancer—such as lymph node positivity or T3 disease—strongly correlate with PTEN deficiency. Dr. Neeraj Agarwal preemptively orders PTEN testing at the locally advanced stage and secures insurance approval while tissue is readily available. If patients eventually develop metastatic disease, clinicians avoid losing crucial four-to-six-week turnaround windows waiting on biopsies and approvals before initiating targeted therapy like capivasertib.

While seen early, even in low-grade cancers, PTEN loss is primarily associated with the cancer's progression to more aggressive forms. It correlates with transitions to higher grades, more advanced stages, and ultimately, metastatic states, marking it as a critical event in the disease's natural history.